<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Combination therapy with 2 or more drugs with different mechanisms of action has been considered a promising strategy for the effective treatment of advanced and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the rational design of combination therapy represents a potential prerequisite for its effectiveness </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, we showed that the combination of oral metronomic S-1 dosing with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (l-OHP)-containing <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "neutral" liposomes exerted excellent antitumor activity </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, we recently designed a <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "cationic" liposome for dual-targeting delivery of l-OHP to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> endothelial cells and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>This targeted liposomal l-OHP formulation showed efficient antitumor activity in a murine <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model, compared with l-OHP-containing <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "neutral" liposomes </plain></SENT>
<SENT sid="5" pm="."><plain>In the present study, we investigated the issue of whether metronomic S-1 dosing with l-OHP-containing <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "cationic" liposomes creates synergy </plain></SENT>
<SENT sid="6" pm="."><plain>Unfortunately, metronomic S-1 dosing resulted in impaired delivery of <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "cationic" liposomes into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue, presumably by decreasing the binding sites on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> blood vessels available for the liposomes </plain></SENT>
<SENT sid="7" pm="."><plain>The anticipated cytotoxic synergistic effect of the combination treatment was not achieved </plain></SENT>
<SENT sid="8" pm="."><plain>Instead, the combination treatment showed lower antitumor efficacy than l-OHP-containing <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "cationic" liposomes alone </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that the combined treatment of S-1 and l-OHP-containing <z:chebi fb="77" ids="46793">PEG</z:chebi>-coated "cationic" liposomes seems to be antagonistic rather than synergistic </plain></SENT>
</text></document>